TOP1 and breast cancer: The desirability of targeting S-phase as a mode of action of breast cancer therapeutics is underlined by the topoisomerase I (TOP1) inhibitor irinotecan, which is a clinically effective pharmaceutical for advanced and metastatic breast cancer [53].